Sponsor
Joseph Morelle
Representative · D-NY
The resolution raises awareness and spotlights disparities in triple-negative breast cancer—potentially improving education, outreach, and attention to research—but is symbolic and does not commit funding or guaranteed programs, risking limited real-world impact for the communities that need it most.
Women (especially those at risk) will get increased national awareness and education about triple-negative breast cancer through a designated observance day, which can help earlier detection and better-informed patients.
The resolution highlights that TNBC disproportionately affects young, Black, and Hispanic women and people with BRCA mutations, which can direct outreach, screening, and research priorities toward the most affected communities.
Emphasizing TNBC's aggressiveness and higher share of deaths may increase public and scientific attention and create political momentum to pursue more research and improved clinical care.
The designation is largely symbolic and does not provide funding or change clinical care, so it may raise expectations without delivering concrete resources or services.
There is a risk that policymakers or stakeholders will treat an observance day as a substitute for targeted programs or funding, leaving the most affected communities (Black and Hispanic women) without needed interventions.
Based on analysis of 2 sections of legislative text.
Designates March 3, 2025 as National Triple-Negative Breast Cancer Day and records findings about TNBC’s characteristics, burden, and disparities.
Representative · D-NY
Official title: Expressing support for the designation of March 3, 2025, as "National Triple-Negative Breast Cancer Day".
Introduced March 3, 2025 by Joseph Morelle · Last progress March 3, 2025
Designates March 3, 2025 as "National Triple-Negative Breast Cancer Day" and records congressional findings about triple-negative breast cancer (TNBC). The findings describe TNBC as a distinct form of breast cancer (recognized in 2006), note its defined biomarker profile (ER-, PR-, HER2-), estimate it accounts for 10–15% of breast cancer cases and about 25% of U.S. breast cancer deaths, and highlight its greater aggressiveness and disproportionate impact on young women, Black and Hispanic women, and people with BRCA mutations. The resolution is ceremonial: it establishes a national awareness day to draw attention to TNBC, its outcomes, and populations at higher risk, without creating new programs, funding, or regulatory requirements.